ArticleJournal of pharmacy & bioallied sciences2025
Role of Oxidative Stress Markers F2-Isoprostanes and Presenilin-1 in Clinical Diagnosed Alzheimer's Diseases.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Data Mining and Biochemical Profiling Reveal Novel Biomarker Candidates in Alzheimer's Disease.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Oxidative stress is an important component in the pathogenesis of Alzheimer's disease (AD). Materils and Methods: A comparative cross-sectional study was conducted on 140 participants who made up 70 subjects diagnosed with AD and 70 controls. Serum levels of F2-isoprostanes and Presenilin 1 were estimated using ELISA. These markers were significantly elevated in the serum of AD patients, suggesting them to be potential biomarkers for early diagnosis and disease progression. Aim and Objective: In this study, the level of F2-isoprostanes and Presenilin 1 was determined in patients clinically diagnosed with AD, thus establishing a possible relationship between heightened markers for oxidative stress and progression of AD. Results: The results showed significantly elevated levels of F2-isoprostanes (179.38 ± 3.01 pg/mL vs 85.89 ± 0.97 pg/mL, Conclusion: This study provides compelling evidence that oxidative stress, as shown by elevated levels of F2-isoprostanes and Presenilin 1, plays a crucial role in the onset of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.